World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
114
Citations
78374
World Ranking
4621
National Ranking
2509

Donald A. Berry publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Donald A. Berry sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 507 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Donald A. Berry D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Donald A. Berry sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 114 D-Index — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1990 - Fellow of Alfred P. Sloan Foundation
  • 1986 - Fellow of the American Statistical Association (ASA)

Overview

Donald A. Berry is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine and biochemistry, genetics, and molecular biology, with a particular emphasis on oncology and cancer research.

Their published work spans several subfields including oncology, cancer research, statistics and probability, radiology, nuclear medicine and imaging, as well as pulmonary and respiratory medicine. The main topics addressed in their research include breast cancer treatment studies, cancer genomics and diagnostics, statistical methods in clinical trials, cancer treatment and pharmacology, HER2/EGFR in cancer research, radiomics and machine learning in medical imaging, and advanced breast cancer therapies.

Some of the recent papers authored or co-authored by Donald A. Berry are:

  • "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody" (2021, Alzheimer s Research & Therapy)
  • "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer" (2020, JAMA Oncology)
  • "Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia" (2020, JAMA Oncology)
  • "Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery" (2021, The Lancet Oncology)
  • "Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial" (2021, Cancer Cell)

Frequent co-authors collaborating with Donald A. Berry include:

  • Laura J. Esserman
  • Christina Yau
  • Angela DeMichele
  • Douglas Yee
  • Nola M. Hylton

The scientist has published extensively in several key venues, notably:

  • Journal of Clinical Oncology
  • Cancer Research
  • UNC Libraries
  • Neuro-Oncology
  • Clinical Cancer Research

Their contributions have been recognized through awards such as:

  • Fellow of Alfred P. Sloan Foundation (1990)
  • Fellow of the American Statistical Association (ASA) (1986)

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Effect of Screening and Adjuvant Therapy on Mortality From Breast Cancer

    Donald A. Berry;Kathleen A. Cronin;Sylvia Plevritis;Dennis G. Fryback

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

    S. Eva Singletary;Craig Allred;Pandora Ashley;Lawrence W. Bassett

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

    Joe Y Chang;Suresh Senan;Marinus A. Paul;Reza John Mehran

  • Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review

    Peter B. Bach;Joshua N. Mirkin;Thomas K. Oliver;Christopher G. Azzoli

  • Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial

    David J. Wilber;Carlo Pappone;Petr Neuzil;Angelo De Paola

  • The decrease in breast-cancer incidence in 2003 in the United States

    Peter M. Ravdin;Kathleen A. Cronin;Nadia Howlader;Christine D. Berg

  • c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

    Hyman B. Muss;Ann D. Thor;Donald A. Berry;Timothy Kute

  • Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

    Kevin S. Hughes;Lauren A. Schnaper;Jennifer R. Bellon;Constance T. Cirrincione

  • Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer

    Kevin S. Hughes;Lauren A. Schnaper;Donald Berry;Constance Cirrincione

  • Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

    William M. Sikov;Donald A. Berry;Charles M. Perou;Baljit Singh

  • Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

    M C Liu;G R Oxnard;E A Klein;C Swanton

  • Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

    Donald A. Berry;Constance Cirrincione;I. Craig Henderson;Marc L. Citron

  • Determining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2

    Giovanni Parmigiani;Donald A. Berry;Omar Aguilar

  • Meta-analyses of Colorectal Cancer Risk Factors

    Constance M. Johnson;Caimiao Wei;Joe E. Ensor;Derek J. Smolenski

  • HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

    Daniel F. Hayes;Ann D. Thor;Lynn G. Dressler;Donald Weaver

  • Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer

    Daniel R. Budman;Donald A. Berry;Constance T. Cirrincione;I. Craig Henderson

Frequent Co-Authors

Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Christina Yau
Christina Yau University of California, San Francisco
Eric P. Winer
Eric P. Winer Yale University
Angela DeMichele
Angela DeMichele University of Pennsylvania
Laura J. van't Veer
Laura J. van't Veer University of California, San Francisco
Clifford A. Hudis
Clifford A. Hudis Memorial Sloan Kettering Cancer Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Kathy S. Albain
Kathy S. Albain Loyola University Chicago
Douglas Yee
Douglas Yee University of Minnesota
Judy C. Boughey
Judy C. Boughey Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering a career in Medicine or related fields in the USA, a variety of online degree options can help jumpstart your journey—or advance your expertise. These pathways offer flexibility, affordability, and specialization, making them popular choices for students and working professionals alike.

Aspiring practical nurses looking for convenient study formats may consider an lpn program, which allows you to start working in healthcare quickly due to its focused and accelerated curriculum. If your interest is in leadership, management, or healthcare business operations, consider the cheapest online healthcare administration degree to gain essential organizational skills while controlling costs.

Nurses aiming for higher qualifications often pursue a Doctor of Nursing Practice through dnp programs without dissertation, ideal for those who want to focus on clinical practice rather than heavy research. Additionally, mental health is an essential field in medicine today, and the psych np programs provide an accelerated route to specialize in psychiatric and mental health care. Together, these pathways widen opportunities in healthcare beyond the traditional MD route.

Best Scientists Citing Donald A. Berry

Trending Scientists

Recently Published Articles